The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other ...

President Donald Trump’s latest bid to slash prescription drug prices has once again stirred heated debate about the high ...

U.S. President Donald Trump's executive order on drug pricing threatens Roche's planned $50 billion investment in the United ...

Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...

Though Eli Lilly and Novo Nordisk have recently taken steps to make their uber-popular GLP-1 drugs more affordable for ...

A global trial reveals tirzepatide helps people lose more weight faster than semaglutide. This breakthrough could change ...

A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap, while ...

On Monday’s episode of Mad Money, Jim Cramer broke down the day’s market rally and argued in favor of staying invested, even ...

Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with ...

Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...

Roche is among several drugmakers to announce large-scale U.S. investments in response to Trump's push to onshore ...

GSK is acquiring an experimental medicine from a Cambridge biotech to shore up its drug pipeline and muscle into the ...